abstract: A phase II evaluation of Lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A GOG group study

Conclusions

Lapatinib has minimal activity in recurrent ovarian cancer. Ki-67 expression may be associated with prior PFS and a polymorphism in EGFR exon 20 (2361G>A, Q787Q).

---

Highlights

► Lapatinib has minimal activity in unselected recurrent ovarian cancer.
► Ki-67 expression may be associated with prior PFS and a polymorphism in EGFR exon 20.
► EGFR and HER2/neu are overexpressed in a minority of ovarian cancers.